Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cyt 387
2. Cyt-387
3. Cyt387
4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1. Cyt387
2. 1056634-68-4
3. Cyt-387
4. Cyt 387
5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide
6. Cyt 11387
7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
8. Gs-0387
9. Momelotinib (cyt387)
10. Cyt-11387
11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
14. 6o01gms00p
15. Chembl1078178
16. Cyt-0387
17. Cyt11387
18. Mfcd16038899
19. Lm-1149
20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide
21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide
22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-
23. Momelotinib [usan]
24. Momelotinib [usan:inn]
25. Momelotinibum
26. Unii-6o01gms00p
27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
28. C87
29. Momelotinib [inn]
30. Momelotinib (usan/inn)
31. Momelotinib [who-dd]
32. Mls006011154
33. Gtpl7791
34. Schembl2237234
35. Chebi:91407
36. Ex-a260
37. Dtxsid801026049
38. Hms3244k19
39. Hms3244k20
40. Hms3244l19
41. Hms3295i01
42. Hms3655d12
43. Hms3744c15
44. Bcp02328
45. Cyt387, Cyt11387
46. Cyt387,cyt 11387
47. Momelotinib (cyt387,cyt-387)
48. Bdbm50311017
49. Nsc767598
50. Nsc800800
51. S2219
52. Zinc43199890
53. Akos015904624
54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide
55. Bcp9000570
56. Ccg-264946
57. Cs-0053
58. Db11763
59. Nsc-767598
60. Nsc-800800
61. Sb14602
62. Ncgc00244257-01
63. Ncgc00244257-08
64. Ac-23162
65. As-19389
66. Hy-10961
67. Smr004702928
68. Sy060668
69. Ft-0755949
70. Sw219679-1
71. D10315
72. A857769
73. Q252602
74. J-001468
75. J-523159
76. Brd-k87737963-001-01-1
77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide
78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide
80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387
83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
| Molecular Weight | 414.5 g/mol |
|---|---|
| Molecular Formula | C23H22N6O2 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 414.18042397 g/mol |
| Monoisotopic Mass | 414.18042397 g/mol |
| Topological Polar Surface Area | 103 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 615 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of myelofibrosis
Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Omjjara (momelotinib) is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. It is indicated for the treatment of myelofibrosis.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: Omjjara
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GSK’s Omjjara receives Japanese approval for treatment of myelofibrosis
Details : Omjjara (momelotinib) is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. It is indicated for the treatment of myelofibrosis.
Brand Name : Omjjara
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
Omjjara (momelotinib) is an oral JAK1/JAK2 and ACVR1 inhibitor for treating splenomegaly and symptoms in adult myelofibrosis patients with moderate to severe anemia.
Lead Product(s): Momelotinib
Therapeutic Area: Hematology Brand Name: Omjjara
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Lead Product(s) : Momelotinib
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Authorises GSK’s Omjjara (momelotinib)
Details : Omjjara (momelotinib) is an oral JAK1/JAK2 and ACVR1 inhibitor for treating splenomegaly and symptoms in adult myelofibrosis patients with moderate to severe anemia.
Brand Name : Omjjara
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 29, 2024
Details:
GS-0387 (momelotinib) has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1). It is being evaluated for the treatment of myelofibrosis patients with anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GS-0387 (momelotinib) has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1). It is being evaluated for the treatment of myelofibrosis pati...
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Details:
Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: Ojjaara
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.
Brand Name : Ojjaara
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2023
Details:
GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2023
Details:
GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GSK Announces Extension Of Fda Review Period For Momelotinib
Details : GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 16, 2023
Details:
GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1 and JAK2 and activin A receptor type I (ACVR1).
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1 and JAK2 and activin A receptor type I (ACVR1).
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 02, 2022
Details:
GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, and JAK2 and activin A receptor, type I (ACVR1).
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Accepts New Drug Application for GSK’s Momelotinib for the Treatment of Myelofibrosis
Details : GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, and JAK2 and activin A receptor, type I (ACVR1).
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 17, 2022
Details:
Momelotinib (GS-0387), has a differentiated mode of action with inhibitory ability along three key signalling pathways: activin A receptor, type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase (JAK) 1, and JAK2.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: GSK
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition July 01, 2022
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : $1,900.0 million
Deal Type : Acquisition
GSK Completes Acquisition of Sierra Oncology
Details : Momelotinib (GS-0387), has a differentiated mode of action with inhibitory ability along three key signalling pathways: activin A receptor, type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase (JAK) 1, and JAK2.
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : $1,900.0 million
July 01, 2022
Details:
GS-0387 (momelotinib) is a potent, selective and orally bioavailable ACVR1 / ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Brand Name: GS-0387
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Lead Product(s) : Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GS-0387 (momelotinib) is a potent, selective and orally bioavailable ACVR1 / ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.
Brand Name : GS-0387
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
